With only one-third of pancreatic cancer patients advancing to second-line treatment, oncologists must carefully select first-line therapies. This may involve choosing less toxic combinations to preserve patient fitness for subsequent treatments, like emerging KRAS inhibitors, rather than using the most aggressive option upfront.

Given that standard therapies for metastatic pancreatic cancer are not curative, leading oncologists argue that clinical trials should be the primary consideration for all eligible patients. Standard chemotherapy regimens are viewed as fallback options. This approach frames trials as the best path to advancing care, not an experimental last resort.

When communicating with anxious, newly diagnosed patients, oncologists can point to the long-term survival 'tail' on modern immunotherapy trial curves. Simply stating, 'there is a chance that you will be alive and well,' provides crucial hope, reduces anxiety, and helps patients better engage with their treatment plan.

A patient on an experimental pancreatic cancer drug emphasized that its greatest benefit was giving her 10 months of a normal life back—working and being a mother and wife. This highlights how quality of life can be as crucial to patients as traditional efficacy endpoints.

Clinicians identify outdated control arms—like single-agent chemotherapy without newer targeted agents—as a major deterrent for patient trial participation. Patients are unwilling to be randomized to a therapy that doesn't reflect the current, more effective standard of care. This pressure is forcing sponsors and the FDA to design trials with more realistic comparator arms.

The efficacy of new KRAS inhibitors is set to fundamentally shift pancreatic cancer research. These agents are expected to become the new standard therapeutic backbone, meaning future clinical trials will likely test new drugs in combination with a RAS inhibitor, moving beyond chemotherapy-only combinations.

The standard of care for pancreatic cancer includes ordering both germline (inherited) and somatic (tumor-specific) genetic tests at the initial patient visit. This "point-of-care" approach is crucial for identifying targetable mutations early on.

The modern oncologist-patient relationship involves highly informed patients who actively research their condition. They bring specific clinical trial papers to appointments, questioning physicians about median PFS data and control arms, requiring a more collaborative and data-driven discussion about their care.

Patient preference is a powerful force in oncology, with many actively seeking to avoid chemotherapy. In the Resolute 303 trial, patients overwhelmingly hope for the daraxoracib monotherapy arm, signaling a clear demand for effective, chemo-free regimens that will shape future clinical development.